Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

ConferenceBEAM-302Neutral

AI Analysis

Summary

Beam Therapeutics will present updated Phase 1/2 trial data for BEAM-302 in Alpha-1 Antitrypsin Deficiency at the European Respiratory Society Congress 2026 as a late-breaking oral presentation.

Clinical Trial Data

Phase

1/2

Importance:5/10

Sentiment:

0.20

clinical_dataconference_presentationphase_1/2rare_disease

Related Companies

$BEAM

Read the original article

Published by yahoo_finance on July 23, 2026 11:00 AM

Read Original